Pall ups its continuous biomanufacturing game in Kaneka Protein A deal
The supply agreement will see Pall – recently acquired by Danaher – add Kaneka Corporation’s KanCapA affinity capture resin to its downstream bioprocessing tools, offering the sorbent in a range of pre-packed columns and high throughput screening tools to its biomanufacturing customers.
The KanCapA affinity capture resin uses Kaneka’s proprietary recombinant alkaline stable Protein A ligand in combination with a cellulose base matrix to form a monoclonal Antibody (mAb) purification resin the Japanese firm says has a high binding capacity for the increasingly high titres being achieved in the industry.
For continuous bioprocessing, upstream perfusion systems can culture cells continuously for up to 90 days, but the biggest challenge is keeping the process going into the downstream train.
But the addition of Kaneka’s Protein A will help solve this, expanding Pall’s portfolio of continuous bioprocessing and chromatography products, and provide “the key chromatographic step required in a typical MAb purification process” according to General Manager Michael Egholm.
“Our customers will be able to go directly from CHO cell culture in the bioreactor through continuous clarification using Acoustic Wave Separation (AWS) and STAX depth filtration products to provide a continuous feed stream for direct integration with the BioSMB platform.”
The BioSMB tech is a multicolumn continuous chromatography platform acquired from Tarpon Biosystems last March, while the AWS system – described as “a filterless filter” - was licensed from FloDesignSonics in June.
